Abstract Library

#3557 Final analysis of Chromogranin A for neuroendocrine tumor diagnosis in Chilean patients: An updated case-control study

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous and differ geographically. Serum chromogranin A (CgA) is the most used biomarker for NET diagnosis, with a sensitivity of 63-100% and specificity of 95-98% with a cutoff value of 108 ng/mL. Recent studies worldwide have reported varying frequencies of NET patients with high CGA at diagnosis, suggesting that the cutoff value may differ according to each population.

Conference:

Presenting Author: Muñoz Medel M

Authors: Muñoz Medel M, Cordova Delgado M, Duran D, Pinto M, Bravo M,

Keywords: neuroendocrine, chromogranin a, biomarker,

#3272 Carcinoid heart disease in Chilean NET patients with malignant carcinoid syndrome: Long-term cohort from a developing country

Introduction: Carcinoid heart disease (CHD) is an important cause of morbidity in patients with Neuroendocrine Tumors (NET) and could be associated with poorer prognosis. There is scarce data about CHD in low and middle-income countries, and its impact has not been studied in Latin American patients.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Carrillo D

Authors: Carrillo D, Muñoz-Medel M, Pinto M, Retamal I, Bravo L,

Keywords: carcinoid heart disease, carcinoid syndrome, prognostic factors, Latin America,

#3216 Survey for neuroendocrine tumors’ standard of care - A multidisciplinary pilot study in Spanish specialists

Introduction: The standard of care for the treatment of neuroendocrine tumors (NETs) seems to have shifted over the last few years towards a multidisciplinary approach. In Spain, there is a lack of real-world data related to NET management in Medical NETs Specialist population.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Sampedro-Núñez M, Muñoz de Nova J, Vázquez G, Hernando J, Triviño E,

Keywords: online survey, patient care, clinical guidelines, research, training,

#3137 Empowerment survey for patients with neuroendocrine tumors - A pilot study in Spanish population

Introduction: Quality of life is very important in patients with neuroendocrine tumors (NET), but other aspects such as satisfaction and empowerment of patients have been less studied. In Spain, there is a lack of validated cancer empowerment questionnaires.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hernando J

Authors: Hernando J, Sampedro-Núñez M, Muñoz de Nova J, Triviño E, Vázquez G,

Keywords: empowerment, online survey, patient advocacy,

#2808 Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile

Introduction: Clinical features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and their repercussions on health-related quality of life (HRQoL) have not been widely studied in Hispanic populations.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carrillo D

Authors: Carrillo D, Munoz-Anguita G, Madison A, Retamal I, Pinto M,

Keywords: Neuroendocrine, Carcinoid, Health-related quality of life.,